Table 2 Overview of patients analyzed based on panel data, only tumor samples were sequenced
From: SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics
Patient | Cancer Type | Panel type | No. of actionable variants | No. of therapies (cancer-type specific, off-label, investigational) | No. of therapies lacking benefit | Comments |
|---|---|---|---|---|---|---|
12 | Fibroblastic osteosarcoma | Oncomine Comprehensive Panel | 0 | 0 | 0 | Only germline variants detected in sample. |
13 | Head and Neck Squamous cell carcinoma | Cancer HotSpot Panel 2.0 | 12 | 12 (6,6,0) | 0 | Various damaging variants in genes of MAPK signaling pathway detected. Tyrosine kinase inhibitor treatment recommended. |
14 | Lung neuroendocrine carcinoma | Cancer HotSpot Panel 2.0 | 1 | 1 (0,1,0) | 0 | Based on FBXW7 D440Y variant mTOR inhibitor treatment recommended. |
15 | Ovarian serous carcinoma | Cancer HotSpot Panel 2.0 | 1 | 1 (1,0,0) | 1 | Based on observed TP53 V173Â L resistance variant doxorubicin treatment recommended and platinum-based treatment discouraged. As indicated in SwissMTB analysis, progressive disease under carboplatin treatment. |
16 | Cutaneous melanoma | Cancer HotSpot Panel 2.0 | 2 | 3 (2,1,0) | 0 | Based on CDKN2A R80* loss-of-function variant off-label treatment with palbociclib recommended. |
17 | Chondrosarcoma | Oncomine Solid Tumor DNA Panel | 10 | 9 (0,9,0) | 3 | Tyrosine kinase inhibitor treatment recommended. Patient was treated with pazopanib, response status unknown. Four resistance-associated variants found: ALK G1202R, KRAS S65Â N, TP53 C275Y, and TP53 G245D. |
18 | Lung adenocarcinoma | Liquid Biopsy, Oncomine Solid Tumor DNA Panel | 0 | 0 | 0 | No tumor DNA contained in sample. |
19 | Lung adenocarcinoma | Liquid Biopsy, Oncomine Solid Tumor DNA Panel | 1 | 0 | 1 | Use of ALK inhibitors discouraged because of ALK G1202R resistance variant. As indicated in SwissMTB analysis, progressive disease under crizotinib treatment. |
20 | Lung squamous cell carcinoma | Oncomine Solid Tumor DNA Panel | 1 | 1 (1,0,0) | 1 | Paclitaxel recommended based on observed TP53 R342* variant.Contradictive case, as a second TP53 R248Q variant is associated with increased chemotherapy resistance. |
21 | Neuroectodermal sarcoma | Cancer HotSpot Panel 2.0 | 0 | 0 | 0 | No variants identified. |
22 | Cutaneous melanoma | Cancer HotSpot Panel 2.0 | 5 | 11 (1,9,1) | 1 | Multi-kinase inhibitor treatment recommended, cisplatin treatment discouraged based on TP53 R273S resistance variant. |
Summary: median (IQR) | 1 (3) | 1 (6) | 0 (1) | Â | ||